Background: The principle of treating-to-target has been successfully applied to many diseases with significant improvement in patient care and as a useful guidance for healthcare providers. Appreciation of the central role for arterial vasodilatation in the pathogenesis of hepatorenal syndrome (HRS) has led to routine use of vasoconstrictors in combination with albumin in patients with HRS. An appropriate target to guide such therapy, however, has not yet been established.
Aims: The purpose of the current study was to identify a suitable target that can predict clinical outcome and guide the medical management of type 1 HRS, a condition associated with very poor prognosis.
Methods: A total of 85 patients with type 1 HRS who received a combination therapy of vasoconstrictors and albumin were enrolled. A potential therapeutic target was identified by univariate and multivariate logistic regression analyses. The treat-to-target concept to guide the management of HRS was then tested via a retrospective cohort study.
Results: A change in mean arterial pressure (MAP) during treatment was identified as a sole independent predictor for patient survival. Compared with mild or no increase in MAP, achievement in a marked increase in MAP of more than 10 mmHg in these patients was associated with better overall survival and transplant-free survival. Increased MAP to higher than 15 mmHg did not result in further improvement in clinical outcome.
Conclusions: A treat-to-target concept by the use of a specific goal of MAP is feasible and may potentially guide the medical management of type 1 HRS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10620-014-3483-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mapping two decades of research in rheumatology-specific journals: a topic modeling analysis with BERTopic.
Ther Adv Musculoskelet Dis
December 2024
Grupo de Patología Musculoesquelética, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos, Madrid, Spain.
Background: Rheumatology has experienced notable changes in the last decades. New drugs, including biologic agents and Janus kinase (JAK) inhibitors, have blossomed. Concepts such as window of opportunity, arthralgia suspicious for progression, or difficult-to-treat rheumatoid arthritis (RA) have appeared; and new management approaches and strategies such as treat-to-target have become popular.
View Article and Find Full Text PDFReview article: Measuring disease severity in inflammatory bowel disease - Beyond treat to target.
Aliment Pharmacol Ther
November 2024
Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
Article Synopsis
- Inflammatory bowel disease (IBD) presents a complex challenge in predicting prognosis due to its varied disease course and the need for comprehensive assessment beyond just current symptoms.
- This review utilizes Medline to explore patterns in disease severity, incorporating factors like genetic profiles, quality of life, and clinical histories to better understand the illness's impact on patients.
- Findings emphasize that IBD severity should account for a combination of inflammatory levels, past complications, and patient-reported outcomes to provide a fuller picture of the disease over time.
Clinical remission and control in severe asthma: agreements and disagreements.
Drugs Context
September 2024
Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.
Over the last two decades, we have witnessed great advancements in our understanding of the immunological pathways of asthma, leading to the development of targeted therapies, such as biologic drugs, that have radically and definitively changed the clinical outcomes of severe asthma. Despite the numerous therapeutic options available, ~4-10% of all people with asthma have severe or uncontrolled asthma, associated with an increased risk of developing chronic oral corticosteroid use, fixed airflow limitation, exacerbations, hospitalization and, finally, increased healthcare costs. The new concept of disease modification in asthma comes from the evolution of asthma management, which encompasses phenotyping patients with different inflammatory endotypes characterizing the disease, followed by the advent of more effective therapies capable of targeting the proximal factors of airway inflammation.
View Article and Find Full Text PDFDevelopment and validation of the 5-Dimension Comprehensive Assessment Scale (5DCAS) for assessing physical function and health in axial spondyloarthritis.
Clin Rheumatol
November 2024
National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Article Synopsis
- The study developed and validated a new patient-reported scale, the Five-Dimensional Comprehensive Assessment Scale (5DCAS), specifically for assessing physical function and health in patients with axial spondyloarthritis (axSpA).
- After a thorough process involving patient surveys and expert consensus, the scale was refined from an initial 135 items down to 25 items across five dimensions, demonstrating strong reliability and validity.
- The 5DCAS shows significant relationships with existing measures of health and disease activity, though further validation in clinical settings is recommended for broader application.
The association between periodontal microbial biomarkers and primary therapy outcome.
Clin Oral Investig
September 2024
Department of Conservative Dentistry and Periodontology, University Hospital, LMU Goethestr. 70, 80336, Munich, Germany.
Objective: This study aims to analyse the association between the baseline microbial load of selected periodontopathogenic bacteria collected from gingival crevicular fluid (GCF) and the primary outcome of steps I and II therapy.
Materials And Methods: 222 patients with stage III periodontitis were included into this retrospective analysis that received steps 1 and 2 periodontal therapy without adjunctive systemic antibiotics. Baseline GCF samples were quantitatively analysed using ELISA-based kits for levels of periodontopathogens (Porphyromonas gingivalis (Pg), Aggregatibacter actinomycetemcomitans (Aa), Prevotella intermedia (Pi), Fusobacterium nucleatum (Fn), Treponema denticola (Td), and Tannerella forsythia (Tf)) and associated with the primary therapy outcome using a "treat-to-target" therapy endpoint (TE) defined as ≤ 4 sites with PD ≥ 5 mm six months after therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!